Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ILX 295501

Drug Profile

ILX 295501

Alternative Names: LY 295501

Latest Information Update: 05 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Genzyme Oncology
  • Class Antineoplastics; Small molecules; Sulfonylureas
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer

Most Recent Events

  • 18 Sep 2018 Genzyme withdraws a phase II trial for Ovarian cancer and Fallopian-tube-cancer (Late stage disease, Metastatic disease, Second line therapy or greater) prior to enrolment in the USA (NCT00005645)
  • 29 Dec 2004 ILEX Oncology has been acquired by Genzyme Corporation
  • 27 May 2004 A clinical study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top